NEOGENOMICS INC — Director's Dealing 2021

Mar 4, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: NEOGENOMICS INC (NEO)
CIK: 0001077183
Period of Report: 2021-03-01

Reporting Person: SHOVLIN ROBERT J. (President, Clinical Services)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-03-01	Common Stock	F	742	—	Disposed	147528	Direct
2021-03-02	Common Stock	F	608	—	Disposed	146920	Direct
2021-03-02	Common Stock	A	6827	—	Acquired	153747	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-03-02	Stock Option (Right to Buy)	$53.17	A	38688	Acquired	2028-03-02	Common Stock (38688.0)	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (Right to Buy)	$8.03	2023-02-26	Common Stock (96167.0)	96167	Direct
Stock Option (Right to Buy)	$19.6	2024-03-01	Common Stock (50173.0)	50173	Direct
Stock Option (Right to Buy)	$28.33	2027-03-02	Common Stock (56271.0)	56271	Direct

Footnotes

F1: Shares surrendered to NeoGenomics Inc. for retirement to satisfy the tax obligations in connection with the March 1, 2021 vesting of restricted stock.

F2: Shares surrendered to NeoGenomics Inc. for retirement to satisfy the tax obligations in connection with the March 2, 2021 vesting of restricted stock.

F3: On February 26, 2018, Mr. Shovlin was granted 288,500 stock options. These options vested ratably over the first three anniversary dates of the grant date.

F4: On March 1, 2019, Mr. Shovlin was granted 66,897 stock options. These options vest ratably over the first four anniversary dates of the grant date.

F5: On March 2, 2020, Mr. Shovlin was granted 56,271 stock options. These options vest ratably over the first four anniversary dates of the grant date.

F6: On March 2, 2021, Mr. Shovlin was granted 38,688 stock options. These options vest ratably over the first four anniversary dates of the grant date